Many HIV service organizations need to grow and change, and that means becoming more reflective of the communities they serve, from bottom to top. Here's some advice on how to get there.
Helping my longtime friend Jeremy find such trials alerted me to this ongoing problem—which will only be reversed if patients, doctors, and trial reviewers keep pushing back on Pharma.
Racial and generational equity demand that leaders with “founder’s syndrome” transfer knowledge, relationships, and connections to new leaders in the movement to end HIV.
In the health care field, we are finally beginning to turn the mirror around and ask, “What are we doing wrong if our BIPOC patients state the same concerns time and time again?”
“ARCA started because there was a heartbreaking need for new drugs to treat HIV,” says Melanie Thompson, M.D. “The landscape for HIV research has indeed changed, largely as a result of our successes.”
“You could think of this as ‘who is in and who is out,’ but in reality [restructuring] is more like changing chairs,” said Carl Dieffenbach, Ph.D.
It’s long been time to put Black experts at the center of public health, make public health visible and relatable to people, and truly understand and address medical mistrust.
We spoke with Amy Killelea at NASTAD, a major national health policy advocacy organization, about the priorities she sees in January 2021 and beyond.
HIV infection rates among Black women in the U.S. have fallen sharply over the past decade, but look closer and the numbers still paint a troubling story.
Already dealing with legal pushbacks, harm-reduction advocates for safe drug consumption sites now have COVID-19 to blame for slow progress.
These HIV Experts Engage Black and Brown Folks on the COVID-19 Vaccine Trials Despite Medical Mistrust
Trump’s “Operation Warp Speed” has left people of color even more wary about research, they say. But it’s still possible, if done the right way by the right people.